FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255133087> ?p ?o ?g. }

• W4255133087 endingPage "618" @default.
• W4255133087 startingPage "614" @default.
• W4255133087 abstract "•Incidence: ■Community: Less than 1%■Hospital: 2% to 7%■Intensive care unit (ICU)/postoperative: 4% to 25%•Risk factors for postoperative renal failure: ■Age >70 years■Insulin-dependent diabetes mellitus■Chronic renal failure■Left ventricular dysfunction•Significant associated mortality in ICU: 43% to 88%•Independent predictor of mortality•Factors increasing mortality: ■Multiorgan failure■Respiratory failure■Cardiovascular dysfunction•Significantly longer length of hospital stay•Formidable health care costs •Alterations in regional blood flow•Increased sensitivity to vasoconstrictor stimuli•Increased sensitivity to renal nerve stimuli•Impaired autoregulation•Endothelial injury•Decreased nitric oxide derived from endothelial nitric oxide synthase•Increased endothelin•Decreased prostaglandins•Leukocyte adhesion to endothelium •Cytoskeletal disruption•Loss of polarity•Tubular obstruction•Abnormal gene expression •Calcium influx•Metalloproteases•Oxygen radicals•Lipid peroxidation•Nitric oxide derived from inducible nitric oxide synthase•Defective heat shock protein response•Phospholipase A2•Calpain•Caspase-1•Neutrophils•T cells •Caspase-3•Endonucleases•Insulin-like growth factor (IGF) deficiency •Endothelial injury and leukocyte infiltration: ■Neutrophils■T lymphocytes■Monocyte/macrophages•Activation of leukocytes by inflammatory mediators •Renal vasoconstriction with intact tubular function•Tumor necrosis factor•Reactive oxygen species•Inducible nitric oxide synthase•Cytokines•Glomerular and vascular microthrombosis•Translation of above experimental results to patients warrants caution •Decrease in glomerular filtration rate (GFR) over a period of hours to days•Failure to excrete nitrogenous waste products•Failure to maintain fluid and electrolyte homeostasis •Increase in blood urea nitrogen only (prerenal acute renal failure [ARF])•Increase in blood urea nitrogen and serum creatinine•Decrease in GFR: ■Calculated GFR: ○Cockcroft-Gault formula (accurate only if renal function is in a steady state)■Measured GFR: ○Creatinine clearance○Urea clearance○Inulin clearance (research tool)○Iodothalamate clearance (gold standard, expensive)•Oliguria, <400 mL urine per day•Serum markers of renal function (future): ■Cystatin C•Urine biomarkers of tubular injury (future): ■Interleukin 18■Kidney injury molecule 1■Neutrophil gelatinase-associated lipocalin •Acute rise in blood urea nitrogen, serum creatinine, or both•Renal hypoperfusion•Bland urine sediment•Fractional excretion of sodium <1%•Return of renal function to normal within 24 to 72 hours of correction of the hypoperfused state •Intravascular volume depletion: ■Hemorrhage■Renal fluid loss■Gastrointestinal losses■Skin loss of sweat■Third-space losses•Reduced cardiac output: ■Congestive heart failure■Cardiogenic shock■Pericardial effusion with tamponad■Massive pulmonary embolism•Increased renal vascular resistance: ■Anesthesia■Hepatorenal syndrome■Prostaglandin inhibitors■Aspirin■Nonsteroidal anti-inflammatory drugs (NSAIDs)•Vasoconstricting drugs: ■Cyclosporine■Tacrolimus■Radiocontrast•Decreased intraglomerular pressure ■Angiotensin-converting enzyme inhibitors■Angiotensin II receptor blockers Common denominator in this setting is obstruction to the flow of urine. •Intraureteral: ■Stones■Blood clots■Papillary necrosis•Extraureteral: ■Bladder■Prostatic cancer■Cervical cancer■Retroperitoneal fibrosis •Prostatic hypertrophy•Prostatic cancer•Bladder cancer•Autonomic neuropathy•Ganglionic blocking agents: urethral obstruction•Valves•Strictures •Bilateral renal artery: ■Stenosis■Thrombosis■Embolism■Operative arterial cross clamping•Bilateral renal vein ■Thrombosis•Small vessel ■Atheroembolic disease■Thrombotic microangiopathy ○Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura○Scleroderma renal crisis○Malignant hypertension○Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome○Postpartum ARF •When ARF develops in glomerulonephritis (GN) setting, rapidly progressive GN (RPGN) should be excluded•Histologically a RPGN manifests as a crescentic GN on kidney histology•Causes of RPGN are classified according to immunofluorescence staining on kidney biopsy: ■Linear immune complex deposition: ○Goodpasture’s syndrome■Granular immune complex deposition: ○Postinfectious○Infective endocarditis○Lupus nephritis○Immunoglobulin A (IgA) nephropathy○Henoch-Schönlein purpura○Membranoproliferative GN■No immune deposits: ○Wegener’s granulomatosis○Polyarteritis nodosa○Churg Strauss○Idiopathic crescentic GN •Causes: ■Bacterial pyelonephritis■Drug-induced acute allergic interstitial nephritis (AIN): ○Antibiotics○Antituberculosis drugs○Diuretics○NSAIDs○Anticonvulsant drugs○Allopurinol○Many other drugs •Causes of acute tubular necrosis (ATN): ■Renal ischemia: ○Sepsis○Shock○Hemorrhage○Trauma○Pancreatitis■Exogenous toxins and nephrotoxic drugs: ○Aminoglycosides○Cisplatin○Radiocontrast○Ethylene glycol■Endogenous toxins: ○Myoglobin (rhabdomyolysis)○Hemoglobin (incompatible blood transfusion, acute falciparum malaria)○Uric acid (acute uric acid nephropathy) •Past and current laboratory data•Vital signs•Daily weights•Intake and output•Fluid and medication review•Did ARF develop outside hospital, in hospital but not ICU, or in ICU?•Thorough history and physical examination •Prerenal•Postrenal•GN/vasculitis•AIN•ATN•Ethylene glycol intoxication•Acute uric acid nephropathy•Obstructive uropathy due to sulfadiazine•Rhabdomyolysis •Specific gravity•Sodium•Creatinine•Urea nitrogen•Osmolality •Renal ultrasonography (procedure most widely used)•Isotope renography•Computed tomography•Cystoscopy and retrograde or anterograde pyelography •ARF of unknown cause•Suspicion of GN, systemic disease (eg, vasculitis), or AIN•ATN not recovering after 4 to 6 weeks of dialysis with no more recurrent insults •Not much true necrosis of tubular cells•Tubular swelling and vacuolization•Tubular loss of brush border•Apical blebbing of tubular cytoplasm•Tubular cell loss manifest as gaps in tubular epithelium•Lack of histological findings that predict clinical outcome •Hepatorenal syndrome•Vasomotor ARF due to NSAIDs, cyclosporine, tacrolimus, angiotensin-converting enzyme inhibitors•Radiographic contrast nephropathy•Atheroembolic disease•Thrombotic microangiopathies•Aminoglycoside nephrotoxicity•Rhabdomyolysis•Acute uric acid nephropathy•ARF in patients with acquired immunodeficiency syndrome•ARF in bone marrow transplant patients •Management of the complications of ARF is important•Dialysis is the only Food and Drug Administration-approved treatment•No specific treatments of established ARF •Correct underlying disorder•Monitor response to therapy: ■Daily weight■Clinical examination of volume status■Central venous catheter■Swan-Ganz catheter •Avoidance of renal-dose dopamine•Use of diuretics to convert oliguric to nonoliguric ARF is controversial•Avoidance of nephrotoxic drugs•Adjustment of drug dosages based on measured or best estimate of GFR, not merely on serum creatinine•Nutrition (enteral nutrition preferred) •Indications to start dialysis in ARF: ■Not specific■Absolute indications: ○Pulmonary edema unresponsive to conservative therapy○Hyperkalemia unresponsive to conservative therapy○Metabolic acidosis unresponsive to conservative therapy○Symptomatic uremia: encephalopathy, pericarditis■Individualized by nephrologic consultation•Timing of initiation of dialysis (recent studies): ■“Prophylactic” hemodialysis (HD) in chronic kidney disease patients prior to coronary artery bypass graft may have survival benefit■“Prophylactic” continuous venovenous hemofiltration (CVVH) in high-risk patients may prevent contrast nephropathy•Dose of dialysis: ■Alternate-day HD■Daily HD■Continuous•Main modalities of dialysis: ■Intermittent HD (IHD)■Continuous renal replacement therapy (CRRT): ○CVVH○Continuous venovenous HD (CVVHD)○Continuous venovenous hemodiafiltration (CVVHDF)○Sustained low-efficiency daily dialysis (SLEDD)○Acute peritoneal dialysis (PD)■IHD and CRRT regarded as equivalent methods for ARF treatment■CRRT may be modality of choice in critically ill, hypotensive patients■IHD may be used in mobile, less ill patients without hypotension■Dialysis modality may depend on facility-specific issues: ○Experience○Nursing resources○Cost○Technical proficiency■In summary, choice of IHD versus CRRT should be individualized at nephrology consultation•Type of dialysis membrane: ■Bioincompatible: ○Cellulose○Cuprophane○Hemophane■Biocompatible (most widely used): ○Polyamides○Polycarbonate○Polysulfone•Temporary vascular access: ■Internal jugular vein: ○For longer duration○Lower infection risk○Technically more difficult to insert○Lower failure rate■Femoral vein: ○For shorter duration○Higher infection risk○Technically easier to insert○Higher failure rate■Subclavian vein ○Avoid if possible" @default.
• W4255133087 created "2022-05-12" @default.
• W4255133087 creator A5067507723 @default.
• W4255133087 creator A5072402432 @default.
• W4255133087 date "2005-03-01" @default.
• W4255133087 modified "2023-10-16" @default.
• W4255133087 title "Acute renal failure" @default.
• W4255133087 doi "https://doi.org/10.1053/j.ajkd.2004.12.008" @default.
• W4255133087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15754287" @default.
• W4255133087 hasPublicationYear "2005" @default.
• W4255133087 type Work @default.
• W4255133087 citedByCount "3" @default.
• W4255133087 crossrefType "journal-article" @default.
• W4255133087 hasAuthorship W4255133087A5067507723 @default.
• W4255133087 hasAuthorship W4255133087A5072402432 @default.
• W4255133087 hasBestOaLocation W42551330871 @default.
• W4255133087 hasConcept C126322002 @default.
• W4255133087 hasConcept C134018914 @default.
• W4255133087 hasConcept C142225936 @default.
• W4255133087 hasConcept C159641895 @default.
• W4255133087 hasConcept C2777622882 @default.
• W4255133087 hasConcept C2780306776 @default.
• W4255133087 hasConcept C2780472472 @default.
• W4255133087 hasConcept C2780972559 @default.
• W4255133087 hasConcept C519581460 @default.
• W4255133087 hasConcept C71924100 @default.
• W4255133087 hasConceptScore W4255133087C126322002 @default.
• W4255133087 hasConceptScore W4255133087C134018914 @default.
• W4255133087 hasConceptScore W4255133087C142225936 @default.
• W4255133087 hasConceptScore W4255133087C159641895 @default.
• W4255133087 hasConceptScore W4255133087C2777622882 @default.
• W4255133087 hasConceptScore W4255133087C2780306776 @default.
• W4255133087 hasConceptScore W4255133087C2780472472 @default.
• W4255133087 hasConceptScore W4255133087C2780972559 @default.
• W4255133087 hasConceptScore W4255133087C519581460 @default.
• W4255133087 hasConceptScore W4255133087C71924100 @default.
• W4255133087 hasIssue "3" @default.
• W4255133087 hasLocation W42551330871 @default.
• W4255133087 hasLocation W42551330872 @default.
• W4255133087 hasOpenAccess W4255133087 @default.
• W4255133087 hasPrimaryLocation W42551330871 @default.
• W4255133087 hasRelatedWork W1623258072 @default.
• W4255133087 hasRelatedWork W1972190589 @default.
• W4255133087 hasRelatedWork W1999680982 @default.
• W4255133087 hasRelatedWork W2008087125 @default.
• W4255133087 hasRelatedWork W2087337247 @default.
• W4255133087 hasRelatedWork W2089295326 @default.
• W4255133087 hasRelatedWork W2093911704 @default.
• W4255133087 hasRelatedWork W2113143771 @default.
• W4255133087 hasRelatedWork W2410557993 @default.
• W4255133087 hasRelatedWork W4248549364 @default.
• W4255133087 hasVolume "45" @default.
• W4255133087 isParatext "false" @default.
• W4255133087 isRetracted "false" @default.
• W4255133087 workType "article" @default.